Trial Profile
A retrospective chart review investigating efficacy of Pembrolizumab in patients with gastrointestinal malignancies with defective DNA mismatch repair.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Cholangiocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2017 New trial record
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology